Application of TNFRSF1B gene as a biomarker in identifying exhausted T cells

By using single-cell sequencing technology, the TNFRSF1B gene was discovered as a marker of exhausted T cells in the tumor microenvironment of ovarian cancer. This solves the problem of low response rate of ovarian cancer to PD-L1/PD-1 inhibitor therapy in existing technologies, and enables accurate identification and regulation of exhausted T cells, thereby improving T cell activity and tumor treatment efficacy.

CN115287362BActive Publication Date: 2024-11-22BEIJING OBSTETRICS & GYNECOLOGY HOSPITAL CAPITAL MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211045366.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-08-30
Publication Date
2024-11-22
Estimated Expiration
2042-08-30

AI Technical Summary

Technical Problem

In existing technologies, tumors such as ovarian cancer have low response rates to PD-L1/PD-1 inhibitor treatment, and traditional bulk RNA sequencing technology cannot effectively analyze the association between various cell types in the tumor microenvironment, resulting in a lack of effective biomarkers for evaluating T cell activity and affecting treatment efficacy.

Method used

Single-cell sequencing technology was used to analyze various cell types in the tumor microenvironment of ovarian cancer, construct cell lineage differentiation trajectories, and find that the TNFRSF1B gene is highly expressed in exhausted T cells, serving as a biomarker for identifying exhausted T cells. T cell activity was identified and regulated by detecting or inhibiting the expression level of this gene.

Benefits of technology

By detecting and regulating the TNFRSF1B gene, exhausted T cells can be accurately identified, the killing ability of T cells can be improved, the treatment effect of tumors such as ovarian cancer can be improved, the understanding of the tumor microenvironment can be expanded, new immunotherapy targets can be provided, and the survival rate of patients can be improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0003822195470000011
    Figure HDA0003822195470000011
  • Figure HDA0003822195470000021
    Figure HDA0003822195470000021
  • Figure HDA0003822195470000031
    Figure HDA0003822195470000031
Patent Text Reader

Abstract

The present invention proposes the application of TNFRSF1B gene as a biomarker in identifying exhausted T cells, and specifically proposes a biomarker for identifying exhausted T cells, wherein the biomarker is selected from the TNFRSF1B gene or a protein or protein fragment encoded and expressed by the TNFRSF1B gene. The TNFRSF1B gene or the protein or protein fragment encoded and expressed by the TNFRSF1B gene can be used as a target for the diagnosis and treatment of tumors, providing more possibilities for immunotherapy, improving the patient's survival cycle, and also providing new ideas for the development of immunotherapy drugs, which has important scientific research and clinical application value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the biological field, and in particular to the application of TNFRSF1B gene as a biomarker in identifying exhausted T cells. Background Art

[0002] With the development of science and technology, immunotherapy has provided a new treatment approach for a variety of tumors and has become a hot topic in tumor treatment today. Immune checkpoints refer to signal pathways that maintain the body's own immune tolerance, regulate immune response responses, and produce strong immunosuppression. Blocking the activity of these molecules can enhance T cell activity and the ability to kill cancer cells. At present, a variety of immune checkpoint molecules have been identified, including cytotoxic T cell-associated antigen 4 (CTLA-4), programmed death molecule 1 (PD-1), programmed death ligand 1 (PD-L1) and PD-L2. PD-1 antibodies have been approved for use in a variety of indications in many countries. However, some cancers (such as ovarian cancer OC) have not benefited from the existing PD-L1 / PD-1 inhibitor treatment, and the response rate is low. The efficacy of ICI treatment for cytotoxic T lymphocyte-associated protein 4 (CTLA-4) or programmed death ligand 1 (PD-L1) / programmed cell death protein (PD-1) is limited, with a response rate of only 10-15%. Existing studies have shown that the low response rate of OC to PD-L1 inhibition cannot be attributed entirely to the low expression of PD-L1 in tumor cells. For example, although nearly two-thirds of OC highly express PD-L1, they still respond poorly to PD-L1 / PD-1. This suggests that PD-1 and CTLA-4 may not be the main T cell inhibitory receptors of OC, and it is urgent to conduct in-depth research on their T cell exhaustion mechanisms and discover new T cell exhaustion receptors to improve the efficacy of diseases such as ovarian cancer. Therefore, in recent years, the academic community has been looking for effective immunotherapy markers based on T cell activity to determine the killing ability and activity of T cells infiltrating the tumor microenvironment, and it is urgent to find more effective and specific tumor markers to improve tumor prognosis. Summary of the invention

[0003] The present invention aims to solve at least one of the technical problems existing in the prior art to at least a certain extent.

[0004] It should be noted that the present invention is completed based on the following findings of the inventors:

[0005] In the past, the evaluation methods that affect T cell activity were often based on the number of T cells or the proportion of T cells, but there is still a lot of clinical evidence to prove the defects and ineffectiveness of this evaluation method. In addition, the study of T cells also often focuses on the relationship between T cells themselves or T cells and tumor cells. Tumor heterogeneity is a key factor in the diversity of its outcomes. The association between various cells in the microenvironment may be an important clue to discover key factors. Therefore, it is necessary to consider all cell types in the tumor microenvironment and their interactions with each other. Previous studies were based on ordinary bulk RNA sequencing technology. Although the traditional bulk RNA sequencing technology has provided a lot of perspectives on tumor growth and evolution, the signals displayed by some specific cell populations or cell states will be masked during bulk sequencing, and this specific cell population or state is sometimes very critical, such as tumor stem cells and TILs related to tumor treatment response. Therefore, bulk RNA cannot achieve gene feature analysis at the level of single cells, nor can it well interpret the association between various cell types.

[0006] Single-cell sequencing has become an ideal tool for single-cell research due to its high accuracy and specificity. It can carry out unbiased high-throughput research with minimal sample input. It can simultaneously analyze the transcriptome and functional status of individual cells, construct the differentiation trajectory of cell lineages, and create a molecular map of cell development lineages, thereby discovering new cell subpopulations or important regulatory genes, and has higher sensitivity in quantifying rare variants and transcripts.

[0007] In view of this, the inventors selected different types of ovarian cancer, analyzed the transcriptome and functional status of individual cells with the help of single-cell sequencing technology, constructed the differentiation trajectory of the cell lineage, created a molecular map of the cell development lineage, and comprehensively explained the association between T cells and various cell types in the tumor microenvironment (such as epithelial cells, endothelial cells, monocytes, etc.), and found that ovarian cancer T cells had high levels of infiltration. Further, the T cells in the tumor microenvironment were divided into different subpopulations, and the main gene characteristics and possible functions and pathways of action of the cell subpopulations that played a major exhaustion role were studied. By comparing the gene lineages of exhausted and non-exhausted T cells, the TNFRSF1B gene was screened to be highly expressed in exhausted T cells of various tumor types, and the highly expressed TNFRSF1B gene in ovarian cancer tissue would affect the patient's prognosis and survival cycle. Further, after in-depth research, it was found that high expression of the TNFRSF1B gene inhibited the ability of T cells to secrete IFN-γ. Thus, it is proved that TNFRSF1B specifically affects the activity and exhaustion of T cells in ovarian cancer, and this gene is expected to become an effective indicator for identifying the killing ability of infiltrating T cells in patients with ovarian cancer, thereby judging the prognosis of patients with ovarian cancer and the choice of immunotherapy. At the same time, the inventors analyzed the data of other tumors such as liver cancer and breast cancer, and found that the TNFRSF1B gene is also highly expressed on the exhausted T cells of these tumors, so the TNFRSF1B gene may be an exhaustion marker and inhibitory receptor that can be applied to a variety of tumor types.

[0008] To this end, in one aspect of the present invention, the present invention provides a biomarker for identifying exhausted T cells. According to an embodiment of the present invention, the biomarker is selected from the TNFRSF1B gene or a protein or protein fragment encoded and expressed by the TNFRSF1B gene.

[0009] In another aspect of the present invention, the present invention proposes the use of a reagent for detecting the expression of TNFRSF1B gene or the expression of a protein or protein fragment encoded by TNFRSF1B gene in preparing a kit. According to an embodiment of the present invention, the kit is used to identify exhausted T cells.

[0010] In another aspect of the present invention, the present invention provides the use of a preparation for inhibiting the expression of TNFRSF1B gene in preparing a drug. According to an embodiment of the present invention, the drug is used to inhibit T cell exhaustion or promote T cells to secrete IFN-γ.

[0011] In another aspect of the present invention, the present invention provides the use of an agent for deleting the TNFRSF1B gene in preparing a kit. According to an embodiment of the present invention, the kit is used to inhibit T cell exhaustion or promote T cells to secrete IFN-γ.

[0012] In another aspect of the present invention, the present invention provides a modified T cell. According to an embodiment of the present invention, the modified T cell is selected from exhausted T cells in which the expression of TNFRSF1B gene is suppressed or knocked out.

[0013] In another aspect of the present invention, the present invention provides a method for screening immunotherapy drugs. According to an embodiment of the present invention, the method comprises: co-culturing a candidate drug with T cells, wherein the TNFRSF1B gene of the T cells is highly expressed; detecting the expression of the TNFRSF1B gene of the T cells before and after the co-culture; wherein, compared with before the co-culture, the downregulation of the TNFRSF1B gene of the T cells after the co-culture is an indication that the candidate drug is a target drug.

[0014] In another aspect of the present invention, the present invention provides a non-diagnostic method for identifying exhausted T cells. According to an embodiment of the present invention, the method comprises: detecting the expression amount of TNFRSF1B gene of candidate T cells or the expression amount of protein or protein fragment encoded and expressed by TNFRSF1B gene; when the expression amount of TNFRSF1B gene or the expression amount of protein or protein fragment encoded and expressed by TNFRSF1B gene is higher than the normal level, it is an indication that the candidate T cells are exhausted T cells.

[0015] In another aspect of the present invention, the present invention provides a non-therapeutic method for inhibiting T cell exhaustion or promoting T cell secretion of IFN-γ. According to an embodiment of the present invention, the method comprises: inhibiting the expression of TNFRSF1B gene of T cells or knocking out TNFRSF1B gene.

[0016] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] The above and / or additional aspects and advantages of the present invention will become apparent and easily understood from the description of the embodiments in conjunction with the following drawings, in which:

[0018] Figure 1 The diagram shows the cell clustering and analysis in the tumor microenvironment of ovarian cancer according to Example 1 of the present invention, wherein A: UMAP analysis shows the cell clustering in the tumor microenvironment; B: Bubble chart shows the characteristic genes of different cell subpopulations; C: Ratios of 9 cell types in different tissues; D: UAMP chart shows the gene expression specific to different subpopulations; E: Violin chart shows the CNV levels in 9 cell types in different tissues.

[0019] Figure 2The single-cell sequencing analysis according to Example 2 of the present invention is shown, wherein A: UMAP diagram shows the classification of T cell subsets; B: UAMP diagram shows the gene expression of different T subgroups; C: pie chart describes the proportion of various T cell subsets in different tissues; D: RNA rate analysis indicates the differentiation direction of different T cell subsets; E: Cibersortx-based analysis of different CD8 + T cell subset scores show their relationship with survival; F: UMAP diagram shows the main functional gene sets of exhausted T cell subsets; G: Multicolor immunofluorescence staining shows CD3 + CD8 + The presence of exhausted T cells is marked by white arrows; scale bar represents 50 μm.

[0020] Figure 3 The results show that the CD8 + T cell related gene analysis, where A: heat map showing exhausted and non-exhausted infiltrating CD8 + Differentially expressed genes between T cells; B: Venn diagram showing the exhausted CD8 + The overlap of T cell genes with those in the study of Zheng and Tirosh, 9 overlapping genes were screened; C: Violin plot shows that the potential exhaustion genes screened are in the exhaustion of CD8 + T cells and non-depleted CD8 + Gene expression levels of T cells. ****p<0.0001; Student T test; D: Kaplan-Meier curve shows that patients with high expression of TNFRSF1B in ovarian cancer have a poor prognosis; E: Violin plot shows the expression of TNFRSF1B in T cell subsets in various scRNA-seq data; F: Multicolor immunofluorescence staining shows the presence of CD3 in various ovarian cancer subtypes and normal ovaries + CD8 + TNFRSF1B + T cells, scale bar represents 20 μm.

[0021] Figure 4 The CD8 according to Example 4 of the present invention is shown + Analysis of T cell activation, where A: UMAP graph showing the expression of TNFRSF1B in T cell subsets, from bottom to top, indicating low to high expression; BD: Human PBMCs were stimulated in vitro with anti-CD3 and anti-CD28 monoclonal antibodies for 2 and 5 days. A gate was set for each designated cell population (CD8 T cells: CD3 + CD8 + , CD4 T cells: CD3 + CD4 + , Tregs: CD3+ CD4 + CD25 + Foxp3 + ), TNFRSF1B expression was determined by flow cytometry (left) and statistical analysis (right), data are expressed as mean ± SEM n = 6, ****p < 0.0001; E: Sorting of TNFRSF1Bhigh and TNFRSF1Blow CD8 + Representative flow cytometry analysis (left) and ELISA quantification (right) of human IFN-γ in the cell supernatant of T cells; ****p<0.0001; data are expressed as mean±SEM n=3; F: Human PBMCs were stimulated for 2 days in the same manner; in CD8 + T cells were gated and the expression of TNFRSF1B, PD-1 and LAG-3 was determined by FACS. The data are presented as mean ± SEM. n = 6; G: CD8 + Flow cytometric plots of expression of TNFRSF1B and exhaustion markers on T cells. DETAILED DESCRIPTION

[0022] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be construed as limiting the present invention. If no specific techniques or conditions are specified in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. The reagents or instruments used that do not specify the manufacturer are all conventional products that can be obtained commercially.

[0023] Biomarkers for identifying exhausted T cells

[0024] In one aspect of the present invention, the present invention proposes a biomarker for identifying exhausted T cells. According to an embodiment of the present invention, the biomarker is selected from the TNFRSF1B gene or the protein or protein fragment encoded and expressed by the TNFRSF1B gene. The inventors found that the expression level of the TNFRSF1B gene in exhausted T cells is significantly higher than the normal level. Therefore, the TNFRSF1B gene or the protein or protein fragment encoded and expressed by the TNFRSF1B gene can be used as a marker to identify exhausted T cells. The inventors verified the accuracy of the identification results by methods such as ROC curves.

[0025] The term "normal level" described in the present invention refers to the expression level of the TNFRSF1B gene in non-exhausted T cells or the expression level of the protein or protein fragment encoded by the TNFRSF1B gene.

[0026] According to an embodiment of the present invention, the T cells are selected from CD8 +T cells, preferably infiltrating CD8 + T cells.

[0027] Use of a reagent for detecting the expression of TNFRSF1B gene or the expression of a protein or protein fragment encoded by TNFRSF1B gene in preparing a kit

[0028] In another aspect of the present invention, the present invention proposes the use of a reagent for detecting the expression amount of the TNFRSF1B gene or the expression amount of the protein or protein fragment expressed by the TNFRSF1B gene in preparing a kit. According to an embodiment of the present invention, the kit is used to identify exhausted T cells. As mentioned above, the TNFRSF1B gene is highly expressed in exhausted T cells, and further, by detecting the expression amount of the TNFRSF1B gene or the expression amount of the protein or protein fragment expressed by the TNFRSF1B gene, the exhausted T cells can be accurately identified.

[0029] It should be noted that the present invention does not strictly limit the type of reagent, as long as it can detect the expression level of the TNFRSF1B gene or the expression level of the protein or protein fragment encoded by the TNFRSF1B gene, it can be a nucleic acid (such as a primer, a probe), a ligand, an enzyme, an antibody, an indicator molecule (such as a fluorescent substance, a radioactive substance, an enzyme), etc., and can be flexibly selected according to actual conditions.

[0030] According to an embodiment of the present invention, the T cells are selected from CD8 + T cells, preferably infiltrating CD8 + T cells.

[0031] According to an embodiment of the present invention, the kit is used to determine the infiltrating CD8 + T cell killing ability.

[0032] According to an embodiment of the present invention, the kit is used for prognosis judgment and selection of immunotherapy for cancer patients.

[0033] The term "immunotherapy" used in the present invention is also called "immunotherapeutic method", which refers to a treatment method that artificially enhances or suppresses the body's immune function to achieve the purpose of treating the disease based on the body's low or hyperimmune state.

[0034] According to an embodiment of the present invention, the cancer is ovarian cancer, breast cancer, lung cancer, nasopharyngeal cancer, liver cancer, gastric cancer, esophageal cancer, colorectal cancer, pancreatic cancer, melanoma, skin cancer, prostate cancer, cervical cancer, leukemia, thyroid cancer, lymphoma, bladder cancer, kidney cancer, uterine cancer, gallbladder cancer, oral cancer, laryngeal cancer, bone cancer, testicular cancer or brain cancer.

[0035] Use of a preparation for inhibiting TNFRSF1B gene expression in preparing medicines

[0036] In another aspect of the present invention, the present invention provides the use of a preparation for inhibiting the expression of TNFRSF1B gene in preparing a drug. According to an embodiment of the present invention, the drug is used to inhibit T cell exhaustion or promote T cells to secrete IFN-γ.

[0037] Studies have found that in exhausted T cells, high expression of the TNFRSF1B gene inhibits the secretion of IFN-γ by T cells. Furthermore, by inhibiting the expression of the TNFRSF1B gene, T cell exhaustion can be effectively inhibited or IFN-γ can be promoted by T cells.

[0038] According to an embodiment of the present invention, the T cells are selected from CD8 + T cells, preferably infiltrating CD8 + T cells; the drug is used to prevent or treat cancer.

[0039] According to an embodiment of the present invention, the cancer is ovarian cancer, breast cancer, lung cancer, nasopharyngeal cancer, liver cancer, gastric cancer, esophageal cancer, colorectal cancer, pancreatic cancer, melanoma, skin cancer, prostate cancer, cervical cancer, leukemia, thyroid cancer, lymphoma, bladder cancer, kidney cancer, uterine cancer, gallbladder cancer, oral cancer, laryngeal cancer, bone cancer, testicular cancer or brain cancer.

[0040] Those skilled in the art will appreciate that the present invention also provides a method for treating or preventing cancer, inhibiting T cell exhaustion, promoting T cell secretion of IFN-γ or promoting T cell proliferation, which method comprises administering a therapeutically effective amount of a preparation that inhibits TNFRSF1B gene expression to an individual in need.

[0041] The medicine according to the embodiment of the present invention can be applied by any method known in the art, including but not limited to intranasal, oral, transdermal, ocular, intraperitoneal, inhalation, intravenous, ICV, intracisternal injection or infusion, subcutaneous, implanted, intravaginal, sublingual, urethral (e.g., urethral suppository), subcutaneous, intramuscular, intravenous, rectal, sublingual, mucosal, eye, spinal cord, intrathecal, intraarticular, intraarterial, subarachnoid, bronchial and lymphatic administration. External preparations can be in the form of gel, ointment, cream, aerosol, etc.; Intranasal preparations can be delivered in the form of spray or droplets; Transdermal preparations can be applied via transdermal patches or ion permeation therapy; Inhalation preparations can be delivered using a sprayer or similar device. Compositions can also be in the form of tablets, pills, capsules, semisolids, powders, sustained-release preparations, solutions, suspensions, elixirs, aerosols or any other suitable compositions.

[0042] For preparing this type of medicine, active ingredient can be mixed with pharmaceutically acceptable carrier, adjuvant and / or excipient according to conventional pharmaceutical compounding technology. Pharmaceutically acceptable carriers that can be used in the present composition include any standard pharmaceutical carrier, such as phosphate buffered saline solution, water and emulsion, such as oil / water or water / oil emulsion, and various types of wetting agents. Composition can contain solid pharmaceutical excipients such as starch, cellulose, talcum, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glyceryl monostearate, sodium chloride, skim milk powder etc. in addition. Liquid and semisolid excipients can be selected from glycerol, propylene glycol, water, ethanol and various oils, including oils from petroleum, animal, plant or synthetic sources, such as peanut oil, soybean oil, mineral oil, sesame oil etc. Liquid carrier, particularly for injection, includes water, saline, aqueous glucose and glycol. Examples of carriers, stabilizers, and adjuvants are found in Remington"s Pharmaceutical Sciences, edited by EW Martin (Mack Publishing Company, 1990, 18th edition). The composition may also include stabilizers and preservatives.

[0043] As used herein, the term "therapeutically effective amount" is an amount sufficient to treat a specified condition or disease or, alternatively, an amount sufficient to obtain a pharmacological response for treating a condition or disease. The method for determining the most effective mode of administration and dosage may vary with the composition used for treatment, the purpose of treatment, the target cells for treatment, and the subject for treatment. The therapeutic dose can usually be titrated to optimize safety and efficacy. Single or multiple administrations may be performed at the dosage level and pattern selected by the attending physician. Suitable dosage forms and methods for administering the agent may be easily determined by those skilled in the art. For example, the composition is administered at about 0.01 mg / kg to about 200 mg / kg, about 0.1 mg / kg to about 100 mg / kg, or about 0.5 mg / kg to about 50 mg / kg. When the compound described herein is administered in combination with another agent or therapy, the effective amount may be lower than the amount when the agent is used alone.

[0044] According to an embodiment of the present invention, it can be administered alone or in combination with other drugs to treat or prevent the diseases described above for a short or long time. The term "individual in need" as used herein refers to any organism with exhausted T cells, such as mammals, including but not limited to humans, rodents, rats, rabbits, apes, cattle, sheep, pigs, dogs, cats, livestock, pets, horses and primates.

[0045] Use of a reagent for deleting the TNFRSF1B gene in preparing a kit

[0046] In another aspect of the present invention, the present invention proposes the use of an agent for deleting the TNFRSF1B gene in preparing a kit. According to an embodiment of the present invention, the kit is used to inhibit T cell exhaustion or promote T cell secretion of IFN-γ. As mentioned above, depleting the high expression of the TNFRSF1B gene in T cells inhibits the secretion of IFN-γ by T cells, and further, by deleting the TNFRSF1B gene, T cell exhaustion can be inhibited and T cells can be promoted to secrete IFN-γ.

[0047] The present invention does not strictly limit the type of reagent for deleting the TNFRSF1B gene, and it can be a conventional gene knockout reagent, such as Cas9 protein, gRNA, etc.

[0048] According to an embodiment of the present invention, the T cells are selected from CD8 + T cells, preferably infiltrating CD8 + T cells; the drug is used to prevent or treat cancer.

[0049] According to an embodiment of the present invention, the cancer is ovarian cancer, breast cancer, lung cancer, nasopharyngeal cancer, liver cancer, gastric cancer, esophageal cancer, colorectal cancer, pancreatic cancer, melanoma, skin cancer, prostate cancer, cervical cancer, leukemia, thyroid cancer, lymphoma, bladder cancer, kidney cancer, uterine cancer, gallbladder cancer, oral cancer, laryngeal cancer, bone cancer, testicular cancer or brain cancer.

[0050] Modified T cells

[0051] In another aspect of the present invention, the present invention provides a modified T cell. According to an embodiment of the present invention, the modified T cell is selected from an exhausted T cell whose TNFRSF1B gene expression is suppressed. By suppressing or knocking out the TNFRSF1B gene of the exhausted T cell, the activity of the T cell can be increased, thereby better activating the immune response.

[0052] According to an embodiment of the present invention, the T cells are selected from CD8 + T cells, preferably infiltrating CD8 + T cells.

[0053] According to an embodiment of the present invention, the modified T cells are selected from CAR-T cells.

[0054] Methods for screening immunotherapy drugs

[0055] In another aspect of the present invention, the present invention proposes a method for screening immunotherapy drugs. According to an embodiment of the present invention, the method comprises: co-culturing a candidate drug with T cells, wherein the TNFRSF1B gene of the T cells is highly expressed; detecting the expression of the TNFRSF1B gene of the T cells before and after the co-culture; wherein, compared with before the co-culture, the TNFRSF1B gene of the T cells after the co-culture is downregulated, which is an indication that the candidate drug is a target drug. If the TNFRSF1B gene in the T cells is higher than the normal level, it indicates that the T cells are exhausted T cells. When the immunotherapy drug is administered, the TNFRSF1B gene can be downregulated, thereby increasing the activity of the T cells and achieving the expected therapeutic effect.

[0056] According to an embodiment of the present invention, the T cells are selected from CD8 + T cells, preferably infiltrating CD8 + T cells.

[0057] Non-diagnostic methods for identifying exhausted T cells

[0058] In another aspect of the present invention, the present invention provides a non-diagnostic method for identifying exhausted T cells. According to an embodiment of the present invention, the method comprises: detecting the expression amount of TNFRSF1B gene of candidate T cells or the expression amount of protein or protein fragment encoded and expressed by TNFRSF1B gene; when the expression amount of TNFRSF1B gene or the expression amount of protein or protein fragment encoded and expressed by TNFRSF1B gene is higher than the normal level, it is an indication that the candidate T cells are exhausted T cells.

[0059] According to an embodiment of the present invention, the T cells are selected from CD8 + T cells, preferably infiltrating CD8 + T cells.

[0060] Non-therapeutic methods to inhibit T cell exhaustion or promote IFN-γ secretion by T cells

[0061] In another aspect of the present invention, the present invention provides a non-therapeutic method for inhibiting T cell exhaustion or promoting T cell secretion of IFN-γ. According to an embodiment of the present invention, the method comprises: inhibiting the expression of TNFRSF1B gene of T cells or knocking out TNFRSF1B gene.

[0062] According to an embodiment of the present invention, the T cells are selected from CD8 + T cells, preferably infiltrating CD8 + T cells.

[0063] Beneficial Effects

[0064] 1. This invention confirms for the first time the role of TNFRSF1B gene in T cell exhaustion and clarifies the changing pattern of TNFRSF1B gene in T cell exhaustion. It aims to develop a diagnostic and therapeutic method targeting TNFRSF1B gene, which is obviously original.

[0065] 2. Elucidate the new mechanism by which the TNFRSF1B gene promotes T cell exhaustion, which will help enrich the mechanism of tumor T cell exhaustion.

[0066] 3. The present invention expands the understanding of the composition and cell state of immune cells in the tumor microenvironment, provides valuable insights into the cytokines that drive the immunosuppressive tumor microenvironment, broadens the understanding of the factors that lead to the failure of immunotherapy, and points out the clinical value of TNFRSF1B, and its possibility as a marker and potential immunotherapy target, which will effectively broaden the treatment methods of tumors, improve the survival rate of tumor patients, and save patients' lives. The elucidation of this mechanism suggests the possibility of TNFRSF1B as a new multifunctional target: a multifunctional target that inhibits the effects of multiple inhibitory immune cells and inhibits tumor cell proliferation, thereby controlling tumor progression. It provides more possibilities for tumor immunotherapy, improves the patient's survival cycle, and also provides new ideas for the selection of new targets and the development of corresponding drugs. At the same time, the present invention starts from basic clinical problems, combines cutting-edge research methods, explores practical problems that need to be solved in the clinic, conforms to the characteristics of the era of the development of precision medicine and translational medicine, and has important clinical significance and translational value in alleviating the medical economic burden, and has important social and economic benefits.

[0067] The scheme of the present invention will be explained below in conjunction with the embodiments. It will be appreciated by those skilled in the art that the following embodiments are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Where specific techniques or conditions are not indicated in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. The reagents or instruments used are not indicated by the manufacturer and are all conventional products that can be obtained commercially.

[0068] Example 1

[0069] Two cases of high-grade serous ovarian cancer tissue (HGS), two cases of borderline ovarian tumor tissue (Borderline), and two cases of normal ovarian tissue (Normal) were collected for 10X single-cell sequencing to comprehensively analyze the ratios and possible interactions of various cells in the ovarian cancer tumor microenvironment. The specific experimental process is as follows:

[0070] 1. Obtaining single cells: Place fresh tissue in tissue storage solution and place on ice to preserve cell viability, then wash and mince on ice. Tumor dissociation solution is used to prepare single cell suspension, dissociate at 37°C, and shake gently for 6 minutes. Filter with a 40μm nylon cell filter to remove red blood cells. Finally, use AO / PI fluorescent dye to stain single cells, and LUNA to check cell viability.

[0071] 2. Single-cell sequencing: Single cells were loaded according to the standard protocol of the Chromium single cell 3′ kit. Library preparation was performed according to the instructions in the 10xGenomics Chromium platform and then sequenced on the Illumina NovaSeq6000System. Low-quality cells (<300 genes / cell, <3 cells / gene, and >20% mitochondrial genes) were filtered. Using Cell Ranger 3.0.1 and Illumina sequencing, the raw sequence files were aligned to the human reference genome (GRCh38) using the STAR algorithm. A gene-barcode matrix containing barcoded cells and gene expression counts was generated and then processed with Seurat v3 (40). Finally, the UMI count data was normalized using a logarithmic transformation. Highly variable genes (HGVs) were selected to merge samples into a merged data set, and the merged gene-by-gene matrix was scaled by dividing the central expression by the standard deviation.

[0072] 3. Dimensionality reduction and clustering: Seurat package and CellMarker database were used to identify major cell types. Unsupervised clustering of PCA was performed using HGVs. PC 1-30 was used to identify different cell populations. For sub-clustering, the same procedures were applied to the restricted dataset to find variable genes, dimension reduction, and clustering. These groups were projected onto uniform manifold approximation and UMAP analysis. Differential gene expression analysis was performed using the “FindMarkers” or “FindAllMarkers” function in Seurat, and the genes were set using default parameters.

[0073] The results are as follows Figure 1As shown in AE, UMAP analysis showed the classification of 9 types of cells in the tumor microenvironment of ovarian cancer and displayed the gene expression specific to different subgroups, as follows: Two epithelial cells (EPCAM, KRT19, CDH1), malignant epithelial cells (PAX8, MUC16, WT1), fibroblasts (ACTA2, MYH11), mesenchymal cells (COL1A1, PDPN), T cells (CD3E, CD8A, CD14), myeloid cells (CD68, CD163), B cells (IGHG1, CD79A, CD79B), endothelial cells (VWF, KDR, CLDN5) were distinguished based on the markers specifically expressed by each cell type. CNV analysis of different tumor tissue types showed that epithelial, fibroblast, and mesenchymal cell clusters in HGSOC showed higher CNV levels compared with other cell types and the same cell types in other tissues ( Figure 1 D). There was no significant difference in CNV levels between normal and borderline tumors. This wide variety of cell subsets and cluster-specific differences in CNV data indicate the high heterogeneity of HGSOC TME. The pie chart depicts the proportion of 9 cell types in different tissues. The proportion of infiltrating T lymphocytes in ovarian cancer is much higher than that in borderline tumors and normal ovarian tissues, confirming the high level of T cell infiltration in ovarian cancer.

[0074] Example 2

[0075] 1. RNA velocity analysis: obtained through analysis of the single-cell sequencing results of Example 1.

[0076] 2. Immunofluorescence: Cells or paraffin sections were fixed in 4% paraformaldehyde (PFA) for 10 min and then permeabilized with 0.1% Triton for 10 min. After blocking with goat serum, the samples were incubated with primary antibodies at 4 °C overnight and then stained with secondary antibodies (streptavidin labeled with Alexa Fluor 488, 594, or 647) and incubated at 37 °C in the dark for 2 h. Finally, the samples were incubated with the nuclear stain 4',6-diamidino-2-phenylindole (DAPI) for 15 min. The prepared samples were imaged by a Nikon A1 confocal microscope.

[0077] The results are as follows Figure 2 As shown in AG, the T cells in the three tissues of Example 1 were further grouped and distinguished according to the markers specifically expressed by each cell type, as follows: exhausted T cells (PD-1, TIM-3, LAG-3), Tcm (CD44, CCR7, IL7R, SELL), Tregs (CD4, FOXP3), NK (KLRB1, KLRD), CD8 +T cells (CD8, GZMK), NKT (CD3, KLRB1, KLRD). Seven major T cell subsets were identified, of which the first subset (C1) and the seventh subset (C7) were both exhausted T cell subsets (determined to be exhausted T cells based on the expression of exhaustion markers PD-1, TIM-3, and LAG-3). Subsequently, the RNA rate was used to identify C1 as the end point of differentiation, C7 as pre-exhausted T cells, and C5 as effector T cells with cytotoxicity. The pie chart describes the proportion of various T cell subsets in different tissues, showing that exhausted T cells are the main dominant cell subset. Based on cibersortx for different CD8 + T cell subset scoring showed its relationship with survival, and the C1 group was found to be significantly associated with poor prognosis; multicolor immunofluorescence staining demonstrated the presence of CD3+CD8+ exhausted T cells in various ovarian cancer types.

[0078] Example 3

[0079] By comparing the gene repertoires of exhausted and non-exhausted T cells (obtained by sequencing analysis of ovarian cancer tissues in Example 1 (including 2 cases each of high-grade serous ovarian cancer tissues (HGS), borderline ovarian tumor tissues (Borderline) and normal ovarian tissues (Normal)), 57 genes related to T cell exhaustion were screened out, and then an intersection analysis was performed with the gene repertoires related to exhausted T cells of other tumor types (hepatocarcinoma, melanoma), and 9 commonly expressed genes were found. The violin plot showed that the potential exhaustion genes screened out were significantly expressed in exhausted CD8 + T cells and non-depleted CD8 + Gene expression levels of T cells. Through in vitro experiments, TNFRSF1B was screened to be highly expressed in exhausted T cells of various tumor types. The Kaplan-Meier curve showed that high expression of TNFRSF1B in ovarian cancer tissues affects the prognosis and survival cycle of patients. Finally, violin plots were used to confirm that TNFRSF1B was expressed in T cell subsets in various scRNA-seq data, and multicolor immunofluorescence staining was used to show the presence of CD3 in various ovarian cancer subtypes and normal ovaries. + CD8 + TNFRSF1B + T cell subsets ( Figure 3 AF).

[0080] Example 4

[0081] 1. PBMC isolation: Peripheral blood mononuclear cell (PBMC) venous blood (10 mL) samples were collected into sodium heparin collection tubes. PBMC were isolated by Ficoll density gradient centrifugation, and PBMC were cultured in complete 1640 medium containing 10% fetal bovine serum and antibiotics and grown in a 37°C, 5% CO2 incubator.

[0082] 2. In vitro T cell activation and flow cytometry analysis: Human PBMCs were cultured in complete 1640 medium containing 10% FBS and antibiotics in the presence of anti-human CD3 and CD28 antibodies. At 2 and 5 days after stimulation, cells were harvested and stained with antibodies (anti-human CD3, CD4, CD8, CD25, TNFRSF1B, Foxp3, PD-1, TIM-3, LAG-3). For intracellular staining, cells were further permeabilized using a fixation and permeabilization kit and stained with antibodies. Samples were detected by flow cytometry and data were processed using FlowJo software.

[0083] The results are as follows Figure 4 As shown in AG, the UMAP graph shows the expression of TNFRSF1B in each T cell subset, from bottom to top, indicating that the expression is from low to high, proving that the TNFRSF1B expression of the C1-depleted T cell subset is the highest; To verify the function of TNFRSF1B, human PBMCs were stimulated in vitro for 2 and 5 days. A gate was set for each designated cell population (CD8 T cells: CD3 + CD8 + , CD4 T cells: CD3 + CD4 + , Tregs: CD3 + CD4 + CD25 + Foxp 3+ ), and the expression of TNFRSF1B was determined by flow cytometry. The results showed that TNFRSF1B was upregulated in activated CD8 T cells, CD4 T cells, and Tregs. + T cells, ELISA detected the expression of human IFN-γ in the supernatant of the two cell types, and found that the ability of T cells with high expression of TNFRSF1B to secrete IFN-γ was significantly reduced, proving that TNFRSF1B inhibits the ability of T cells to secrete IFN-γ, suggesting that TNFRSF1B is a key exhaustion gene that promotes T cell exhaustion.

[0084] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.

[0085] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.

Claims

1. Use of a preparation for inhibiting TNFRSF1B gene expression in preparing a drug, characterized in that: The drug is used to promote T cells to secrete IFN-γ; The T cells are selected from infiltrating CD8+T cells; The drug is used to prevent or treat cancer; The cancer is ovarian cancer, breast cancer, lung cancer, nasopharyngeal cancer, liver cancer, gastric cancer, esophageal cancer, colorectal cancer, pancreatic cancer, melanoma, skin cancer, prostate cancer, cervical cancer, leukemia, thyroid cancer, lymphoma, bladder cancer, kidney cancer, uterine cancer, gallbladder cancer, oral cancer, laryngeal cancer, bone cancer, testicular cancer or brain cancer.

2. Use of a reagent for deleting the TNFRSF1B gene in preparing a kit, characterized in that: The kit is used to promote T cells to secrete IFN-γ; The T cells are selected from infiltrating CD8+T cells; The drug is used to prevent or treat cancer; The cancer is ovarian cancer, breast cancer, lung cancer, nasopharyngeal cancer, liver cancer, gastric cancer, esophageal cancer, colorectal cancer, pancreatic cancer, melanoma, skin cancer, prostate cancer, cervical cancer, leukemia, thyroid cancer, lymphoma, bladder cancer, kidney cancer, uterine cancer, gallbladder cancer, oral cancer, laryngeal cancer, bone cancer, testicular cancer or brain cancer.